Chemotherapy in pancreatic adenocarcinoma

European Review for Medical and Pharmacological Sciences

Volumn 14, Issue 4, 2010, Pages 386-394

  Squadroni, M ^a   Fazio, N ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

5 FU; Adjuvant; Chemoradiation; Chemotherapy of pancreatic neoplasms; Gemcitabine; Neoadjuvant; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; OXALIPLATIN; PEMETREXED;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; REVIEW;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS;

EID: 77953163951     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, XU J, THUN MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. GARCEA G, DENNISON AR, PATTENDEN CJ, NEAL CP, SUTTON CD, BERRY DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9: 99-132.
3. MOON HJ, AN JY, HEO JS, CHOI SH, JOH JW, KIM YI. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas 2006; 32: 37-43.
4. SULTANA A, TUDUR SMITH C, CUNNHINGAM D, STARUNG N, NEOPTOLEMUS JP, CHANEH P. Meta-analysis of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615.
5. BURRIS HA 3RD, MOORE MJ, ANDERSEN J, GREEN MR, ROTHENBERG ML, MODIANO MR, CRIPPS MC, PORTENOY RK, STORNIOLO AM, TARASSOFF P, NELSON R, DORR FA, STEPHENS CD, VON HOFF DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
6. FURUSE J, ISHII H, OKUSAKA T, NAGASE M, NAKACHI K, UENO H, IKEDA M, MORIANE C, YOSHINO M. Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer. Jpn J Clin Oncol 2005; 35: 733-738. (Pubitemid 43091658)
7. GELIBTER A, MALAGUTI P, DI COSIMO S, BRIA E, RUGGERI EM, CARUNI P, CARBONI F, ETORRE GM, PELLICCIOTTA M, GIANNAREKLI D, TERZOLI E, COGNETTI F, MILELLA M. Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree. Cancer 2005; 104: 1237-1245.
8. TEMPERO M, PLUNKETT W, RUIZ VAN HAPEREN V, HAINSWORTH J, HOCHSTER H, LENZI R, ABBRUZZESE J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21: 3402-3408.
9. VELTKAMP SA, BEUNEN JH, SCHELLENS JH. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008; 13: 261-1167
10. LOUVET C, LABIANCA R, HAMMEL P, LLEDO G, ZAMPINO MG, ANDRÉ T, ZANIBONI A, DUCREUX M, AITINI E, TAÏEB J, FAROUX R, LEPERE C, DE GRAMONT A;' GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516. (Pubitemid 46243495)
11. POPLIN E, FEN Y, BERUN J, ROTHENBERG ML, HOCHSTER H, MITCHELL E, ALBERTS S, O'DWYER P, HALLER D, CATALANO P, CELLA D, BENSON AB 3RD. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patient with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27: 3778-3785.
12. CASCINU S, LABIANCA R, CATALANO V, BANNI S, FERRAU F, BERETTA GD, FRONTINI L, FOA P, PANCERA G, PRIOLO D, GRAZIANO F, MARE M, CATALANO G. Weekly gemcitabine and cisplatin chemotherapy: a well tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 2003; 14: 205-208.
13. LOUVET C, ANDRÉ T, LLEDO G, HAMMEL P, BLEIBERG H, BOULEUC C, GAMELIN E, FLESCH M, CVITKOVIC E, DE GRAMONT A. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II Study. J Clin Oncol 2002; 20: 1512-1518.
14. COLUCCI G, GIULIANI F, GEBBIA V, BIGLIETTO M, RABITTI R UOMO G, CIGOLARI S, TESTA A, MAIELLO E, LOPEZ M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: A prospective, randomised phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer 2002; 94: 902-910.
15. HEINEMANN V, QUIETZSCH D, GIESELER F, GONNERMANN M, SCHOKENAS H, ROST A, NEUHAUS H, HAAG G, CLEMES M, HEINRICH B, VEHKING-KAISER U, FUCHS M, FLECKENSTEIN D, GEISERICH W, UTHGENANNT D, EINSELE H, HOLSTEGE A, HINKE A, SCHALHOM A, WILLKOWSKI R. Randomized phase III trial of gemcitabine plus Cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-3952. (Pubitemid 46630743)
16. HERRMANN R, BODOKY G, RUHSTALLER T, GLIMELIUS B, BAJETTA E, SCHÜLLER J,SALETTI P, BAUER J, FIGER A, PESTALOZZI B, KÖHNE CH, MINGRONE W, STEMMER SM, TAMAS K, KORNEK GV, KOEBERLE D, CINA S, BERNHARD J, DIETRICH D, SCHEITHAUER W. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multi-center, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Clin Oncol 2007; 25: 2212-2217.
17. CUNNINGHAM D, CHAU I, STOCKEN C, DEVIES C, DUNN J, VALLE J. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005; 3(Suppl 4): (Abstr PS11).
18. BERLIN JD, CATALANO P, THOMAS JP, KUGLER JW, HALLER DG, BENSON AB. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20: 3270-3275.
19. OETTLE H, RICHARDS D, RAMANATHAN RK, VAN LAETHEM JL, PEETERS M, FUCHS M, ZIMMERMANN A, JOHN W, VON HOFF D, ARNING M, KINDLER HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005; 16: 1639-1645.
20. ROCHA LIMA C, GREEN M, ROTCHE R, MILLER WH, JEFFREY GM, CISAR LA, MORGANTI A, ORLANDO N, GRUIA G, MILLER LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 18: 3776-3783.
21. HEINEMANN V, LABIANCA R, HINKE A, LOUVET C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18: 1652-1659.
22. HEINEMANN V, BOECK S, HINKE A, LABIANCA R, LOUVET C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine based chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82.
23. BRAMHALL SR, SCHULZ J, NEMUNAITIS J, BROWN PD, BAILLET M, BUCKELS JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87: 161-167.
24. VAN CUTSEM E, VAN DE VELDE H, KARASEK P, OETTLE H, VERVENNE WL, SZAWLOWSKI A, SCHOFFSKI P, POST S, VERSLYPE C, NEUMANN H, SAFRAN H, HUMBLET Y, PEREZ RUIXO J, MA Y, VON HOFF D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
25. KINDLER HL, NIEDZWIECKI D, HOLLIS D, ORAEFO E, SCHRAG D, HURWITZ H, MCLEOD HL, MULCAHY MF, SCHILSKY RL, GOLDBERG RM, CANCER AND LEUKEMIA GROUP B. A double-bind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 2007; 25(18S): abst 4508.
26. VAN CUTSEM E, VERVENNE WL, BENNOUNA J, HUMLET Y, GILL S, VAN LAETHEM JL, VERSLYPE C, SCHEITAUER W, SHANG A, COSAERT J, MOORE MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-12223
27. PHILIP PA, BENEDETT JI, FENOGLIO-PREISER C, ZALUPSKI M, LENZ H, O'REILLY E, WONG R, ATKINS J, ABRUZZESE J, BLANKE C. Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma (Pca): SWOG S0205 study. J Clin Oncol 2007; 25(18S): LBA4509.
28. MOORE MJ, GOLDSTEIN D, HAMM J, FIGER A, HECHT JR, GALLINGER S, AU HJ, MURAWA P, WALDE D, WOLFF RA, CAMPOS D, LIM R, DING K, CLARK G, VOSKOGLOUNOMIKOS T, PTASYNSKI M, PARULEKAR W; NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
29. HUGUET F, GIRARD N, GUERCHE CS, HENNEOUIN C, MORNEX F, AZRIA D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27: 2269-2277.
30. GASTROINTESTINAL TUMOR STUDY GROUP. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80: 751-755.
31. MOERTEL CG, FRYTAK S, HAHN RG, O'CONNELL MJ, REITEMEIER RJ, RUBIN J, SCHUTT AJ, WEILAND LH, CHILDS DS, HOLBROOK MA, LAVIN PT, LIVSTONE E, SPIRO H, KNOWLTON A, KALSER M, BARKIN J, LESSNER H, MANN-KAPLAN R, RAMMING K, DOUGLAS HO JR, THOMAS P, NAVE H, BATEMAN J, LOKICH J, BROOKS J, CHAFFEY J, CORSON JM, ZAMCHECK N, NOVAK JW. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710.
32. CHAUFFERT B, MORNEX F, BONNETAUN F, ROUGIER P, MARIETTE C, BOUCHE O, BOSSET JF, APARICIOS T; MINEUR L, AZEDINE A, HAMMEL P, BUTEL J, STREMSDOERFER N, MAINGON P, BEDENNE L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-2001 FFCD/SFRO study. Ann Oncol 2008; 19: 1592-1599.
33. HUGUET F, ANDRE T, HAMMEL P, ARTRU P, BALOSSO J, SELLE F, DENIAUD-ALEXANDRE E, RUSZNIEWSKI P, TOUBOUL E, LABIANCA R, DE GRAMONT A, LOUVET C. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR Phase II and III Studies. J Clin Oncol 2007; 20: 326-331.
34. MARTI JL HICHSTER HS, HIOTIS SP, DONAHE R, RYAN T, NEWMAN E. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 2008; 15: 3521-3531.
35. CHUA YJ, CUNNINGHAM D. Adjuvant treatment for resectable pancreatic cancer. J Clin Oncol 2005; 23: 4532-4537. (Pubitemid 46196583)
36. STOCKEN DD, BUCHLER MW, DERVENIS C, BASSI C, JEEKEL H, KUNKENBUL JH, BAKKEVOLD KE, TAKADA T, AMANO H, NEOPTOLEMOS JP; PANCREATIC CANCER META-ANALYSIS GROUP. Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-1381.
37. NEOPTOLEMOS JP, STOCKEN DD, FRIESS H, BASSI C, DUNN JA, HICKEY H, BEGER H, FERNANDEZ-CRUZ L, DERVENIS C, LACAINE F, FALCONI M, PEDERZOU P, PAP A, SPOONER D, KERR DJ, BUCHLER MW; EUROPEAN STUDY GROUP FOR PANCREATIC CANCER. A randomized trial of chemotherapy and chemoradiotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210.
38. OETTLE H, POST S, NEUHAUS P, GELLERT K, LANGREHR J, RIDWELSKI K, SCHRAMM H, FAHLKE J, ZUELKE C, BURKART C, GUTBERLET K, KETTNER E, SCHMALENBERG H, WEIGANG-KOEHLER K, BECHSTEIN WO, NIEDERGETHMANN M, SCHMIDT-WOLF I, ROLL L, DOERKEN B, RIESS H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277. (Pubitemid 46143304)
39. NEOPTOLEMOS J, BUCHLER M, STOCKEN D, SMITH D, BASSI C, MOORE M, CUNNINGHAM D, DERVENIS D, GOLDSTEIN D. ESPAC3 (v2): a multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 2009; 27: 18s(Suppl; abstr LBA4505).
40. KALSER MH, ELLENBERG SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899-903.
41. YEO CJ, ABRAMS RA, GROCHOW LB, SOHN TA, ORD SE, HRUBAN RH, ZAHURAK ML, DOOLEY WC, COLEMAN J, SAUTER PK, PITT HA, LILLEMORE KD, CAMERON JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single institution experience. Ann Surg 1997; 225: 621-636.
42. KLINKENBUL JH, JEEKEL J, SAHMOUD T, VAN PEL R, COUVREUR ML, VEENHOF CH, ARNAUD JP, GONZALEZ DG, DE WIT LT, HENNIPMAN A, WILS J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative Group. Ann Surg 1999; 230: 776-784.
43. NEOPTOLEMOS JP, STOCKEN DD, DUNN JA, ALMOND J, BEGER HG, PEDERZOU P, BASSI C, DERVENIS C, FERNANDEZ-CRUZ L, LACAINE F, BUCKELS J, DEAKIN M, ADAB FA, SUTTON R, IMRIE C, IHSE I, TIHANYI T, OLAH A, PEDRAZZOU S, SPOONER D, KERR DJ, FRIESS H, BUGHLER MW; EUROPEAN STUDY GROUP FOR PANCREATIC CANCER. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758-768.
44. BUTTURINI G, STOCKEN DD, WENTE MN, JEEKEL H, KLINKENUL JH, BAKKEVOLD KE, TAKADA T, AMANO H, DERVENIS C, BASSI C, BÜCHLER MW, NEOPTOLEMUS JP, PANCREATIC CANCER META-ANALYSIS GROUP. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143: 75-83.
45. STOCKEN DD, BÜCHLER MW, DERVENIS C, BASSI C, JEEKEL H, KUNKENBUL JH, BAKKEVOLD KE, TAKADA T, AMANO H, NEOPTOLEMOS JP. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92(8): 1372-1381. (Pubitemid 40705002)
46. PALMER D, STOCKEN DD, HEWITT H, MARKHAM CE, HASSAN AB, JOHNSON PJ, BUCKELS JA, BRAMHALL SR. A randomized phase II trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14: 2088-2096.
47. HEINRICH S, PESTALOZZI BC, SCHAFER M, WEBER A, BAUERFEIND P, KNUTH A, CLAVIEN RA. Prospecitve phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 2526-2531.
48. TALAMONTI MS, SMAL WJ, MULAHCY MF, WANE J, ATTALURI V, CoLLETTI LM, ZALUPSKI MM, HOFFMAN JP, FREEDMAN GM, KINSELLA T, PHILIP PA, MCGINN O. A multi-institutional phase II trial of preoperative full dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006; 13: 150-158.
49. EVANS DB, VARADHACHARY GR, CRANE CH, SUN CC, LEE JE, PISTERS PWT, VAUTHEY JN, WANG H, CLEARY KR, STAERKEL GA, CHARNSANGAVEJ C, LANO EA, HO L, LENZI R, ABBRUZZESE JL, WOLFF RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502.
50. STESSIN AM, MEYER JE, SHERR DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) Registry. Int J Radiat Oncol Biol Phys 2008; 72: 1128-1133.
51. SPITZ FR, ABBRUZZESE JL, LEE JE, PISTERS PWT, LOWY AM, FENOGUO O, CLEARY KC, JANJAN NA, GOSWITZ MS, RICH TA, EVANS DB. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15: 928-937.
52. VARADHACHARY GR, WOLFF RA, CRANE CH, SUN CC, LEE JE, PISTERS PW, VAUTHEY JN, ABDALLA E, WANG H, STAERKEL GA, LEE JH, ROSS WA, TAMM EP, BHOSALE PR, KRISHNAN S, DAS P, HO L, XIONG H, ABBRUZZESE JL, EVANS DB. Preoperative gemcitabine and cis-platin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-3495.
53. MORGAN MM, PARSELS LA, KOLLAR LE, NORMOLLE DP, MAYBAUM J, LAWRENCE TS. The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer. Clin Cancer Res 2008; 14: 5142-5149.
54. DEMOLS A, MAHIN C, MARÉCHAL R, DELAUNOIT T, BORBATH I, HENDUSZ A, JACOUY C, MITINE C, VAN LAETHEM J. Cetuximab plus chemoradiation combined therapy for locally advanced inoperable pancreatic adenocarcima: A phase I study. J Clin Oncol 2008; 26: (May 20 suppl; abstr 4629).
55. MUNTER M, TIMKE C, ABDOLLAHI A, FRIESS H, JAEGER D, HEEGER S, BUCHLER M, DEBUS J, HUBER P, KREMPIEN R. Final results of a phase II trial [PARC-Study IS-RCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol 2008; 26: (May 20 suppl; abstr 4613).